Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors for the Treatment of Anemia in CKD: Additional Pieces of the Jigsaw Puzzle
- PMID: 34308931
- PMCID: PMC8258577
- DOI: 10.1016/j.ekir.2021.05.017
Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors for the Treatment of Anemia in CKD: Additional Pieces of the Jigsaw Puzzle
Comment on
-
A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study.Kidney Int Rep. 2021 Apr 17;6(7):1829-1839. doi: 10.1016/j.ekir.2021.04.007. eCollection 2021 Jul. Kidney Int Rep. 2021. PMID: 34307977 Free PMC article.
-
A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study.Kidney Int Rep. 2021 May 12;6(7):1840-1849. doi: 10.1016/j.ekir.2021.04.037. eCollection 2021 Jul. Kidney Int Rep. 2021. PMID: 34307978 Free PMC article.
References
-
- U.S. Renal Data System 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States [Table 1.5]. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2020. https://adr.usrds.org/2020/end-stage-renal-disease/1-incidence-prevalenc... Accessed June 22, 2021.
-
- Fibrogen Provides Additional Information on Roxadustat. Accessed May 3, 2021. https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen...
Publication types
LinkOut - more resources
Full Text Sources
